Merck posts Q3 beat as Keytruda offsets sales impact on COVID-19 pill

Oct. 27, 2022 7:09 AM ETMerck & Co., Inc. (MRK)By: Dulan Lokuwithana, SA News Editor2 Comments

Merck & Co. headquarters in Silicon Valley

Sundry Photography/iStock Editorial via Getty Images

Merck (NYSE:MRK) traded higher pre-market Thursday after announcing better than expected financials for Q3 2022 as the company’s oncology franchise led by blockbuster cancer therapy Keytruda negated the sales impact on COVID-19

Recommended For You

Comments (2)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.